Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.01 +2.0%	$3.17	$2.07 ▼ $4.20	$95.02M	0.43	75,989 shs	26,544 shs
RCKT Rocket Pharmaceuticals	$3.35 +0.9%	$3.04	$2.19 ▼ $22.01	$358.24M	0.65	5.84 million shs	4.40 million shs
VIGL Vigil Neuroscience	$8.05	$8.03	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A
YMAB Y-mAbs Therapeutics	$8.54 -0.1%	$5.96	$3.55 ▼ $16.11	$388.50M	0.57	2.08 million shs	1.88 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+2.03%	+2.03%	-2.90%	+17.12%	-8.51%
RCKT Rocket Pharmaceuticals	+0.90%	-10.19%	+11.30%	+35.08%	-81.92%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.12%	+2.16%	+129.34%
YMAB Y-mAbs Therapeutics	-0.12%	+0.12%	+71.83%	+81.32%	-44.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.4781 of 5 stars	3.5	3.0	0.0	1.3	3.3	0.0
RCKT Rocket Pharmaceuticals	4.9086 of 5 stars	4.2	4.0	4.7	2.5	5.0	0.6
VIGL Vigil Neuroscience	1.7896 of 5 stars	3.0	3.0	0.0	0.0	2.5	0.6
YMAB Y-mAbs Therapeutics	2.5108 of 5 stars	2.9	4.0	0.0	1.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.00	Buy	$9.00	199.00% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$16.73	399.50% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	12.67% Upside

Current Analyst Ratings Breakdown

Latest ANIX, RCKT, YMAB, and VIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $10.00
8/20/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/19/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.59 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A
YMAB Y-mAbs Therapeutics	$87.68M	4.43	N/A	N/A	$1.93 per share	4.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	11/6/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	11/6/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	11/14/2025 (Estimated)

Latest ANIX, RCKT, YMAB, and VIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	Q3 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
RCKT Rocket Pharmaceuticals	0.05	6.39	6.39
VIGL Vigil Neuroscience	N/A	2.97	2.97
YMAB Y-mAbs Therapeutics	N/A	4.00	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
RCKT Rocket Pharmaceuticals	98.39%
VIGL Vigil Neuroscience	83.64%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
RCKT Rocket Pharmaceuticals	24.76%
VIGL Vigil Neuroscience	18.01%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

ANIX, RCKT, YMAB, and VIGL Headlines

Recent News About These Companies

Stonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMAB

August 26 at 7:38 AM | marketbeat.com

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62

August 26 at 2:21 AM | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from Analysts

August 25, 2025 | marketbeat.com

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 19, 2025 | globenewswire.com

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13, 2025 | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, RCKT, YMAB, and VIGL Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.01 +0.06 (+2.03%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$3.03 +0.02 (+0.66%)

As of 08:18 AM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.35 +0.03 (+0.90%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$3.36 +0.00 (+0.15%)

As of 08:22 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.54 -0.01 (-0.12%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$8.54 0.00 (0.00%)

As of 08:00 AM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time